HSA
PDLI

Hussman Strategic Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Hussman Strategic Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,087,000
Closed -$9.03M – 228
2014
Q1 		$9.03M Hold
1,087,000
– – 0.68% 68
2013
Q4 		$9.17M Sell
1,087,000
-1,131,000
-51% -$9.53M 0.65% 70
2013
Q3 		$17.7M Sell
2,218,000
-591,000
-21% -$4.75M 0.97% 43
2013
Q2 		$21.7M Buy
+2,809,000
New +$21.9M 0.99% 32

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hussman Strategic Advisors's PDLI Position: Q2 2014 in Review

Hussman Strategic Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q2 2014, closing a stake of 1,087,000 shares — an estimated $9.03M sold.

Hussman Strategic Advisors first reported a position in PDLI in Q2 2013 and held it in 4 quarters. The position peaked at $21.7M in Q2 2013. 222 funds tracked by Wall St. Rank hold PDLI as of Q2 2014.

  • Hussman Strategic Advisors reported no remaining PDL BioPharma, Inc. position as of Q2 2014 after selling out during the quarter.
  • Hussman Strategic Advisors sold 1,087,000 PDL BioPharma, Inc. shares in Q2 2014, an estimated $9.03M.
  • Hussman Strategic Advisors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 4 quarters.
  • Hussman Strategic Advisors's PDL BioPharma, Inc. position peaked at $21.7M in Q2 2013.
  • 222 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2014.

Based on Hussman Strategic Advisors's 13F filing for Q2 2014, filed 1 Aug 2014.